Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer Compugen Ltd. disclosed that it has achieved the initial milestone in the cancer immunotherapy collaboration it entered with Bayer HealthCare. The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. [Compugen Ltd.] Press Release Sorrento Awarded up to $2.6 Million from the National Institutes of Health (NIH) for the Development of New Anti-Bacterial Bispecific Antibodies and Antibody Formulated Drug Conjugates Sorrento Therapeutics, Inc. announced that it has received two NIH small business grants which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. [Sorrento Therapeutics, Inc.] Press Release Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital Advanced Cell Technology, Inc. announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital Fund, LLC. [Advanced Cell Technology, Inc.] Press Release Genocea Announces Positive Top-Line 12-Month Follow-Up Data from Phase I/IIa Clinical Trial for HSV-2 Immunotherapy GEN-003 Genocea Biosciences, Inc. announced positive top-line 12-month follow-up data from a Phase I/IIa study of GEN-003, the company’s immunotherapy candidate against herpes simplex virus type 2 (HSV-2). [Genocea Biosciences, Inc.] Press Release European Medicines Agency Renews Marketing Authorization for ChondroCelect TiGenix NV announced that the Committee for Medicinal Products for Human Use has renewed for an additional five years its marketing authorization for ChondroCelect in all of the 31 countries of the European Union and European Economic Area. [TiGenix NV] Download Press Release Amgen Receives FDA Breakthrough Therapy Designation for Investigational BiTE® Antibody Blinatumomab in Acute Lymphoblastic Leukemia Amgen announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to investigational bispecific T cell engager (BiTE®) antibody blinatumomab, for adults with Philadelphia-negative relapsed/refractory B-precursor acute lymphoblastic leukemia, a rapidly progressing cancer of the blood and bone marrow. [Amgen Inc.] Press Release University of Pennsylvania’s Personalized Cellular Therapy for Leukemia Receives FDA’s Breakthrough Therapy Designation A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia. The investigational therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this classification. [Penn Medicine] Press Release Aratana Therapeutics Files for USDA Product License of AT-014 Canine Osteosarcoma Immunotherapy Aratana Therapeutics, Inc. announced that it has filed for a product license from the United States Department of Agriculture (USDA) for AT-014, a novel her2/neu-directed cancer immunotherapy licensed exclusively from Advaxis, Inc. for the treatment of canine osteosarcoma and other cancers. [Aratana Therapeutics, Inc. (PR Newswire Association LLC)] Press Release Cytori Receives Notice of Intent to Exercise First Contract Option from BARDA Cytori Therapeutics has received preliminary written notice of intent to exercise ‘Option 1’ of the company’s contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. Cytori was awarded a contract with BARDA for the development of Cytori Cell Therapy for thermal burns combined with radiation injury worth up to $106 million. [Cytori Therapeutics] Press Release |